

**InRetail Pharma S.A. and Subsidiaries**

Interim consolidated financial statements as of June 30, 2021,  
(non-audited) and December 31, 2020 (audited) and for the six-  
month period ended June 30, 2021 and 2020

## **InRetail Pharma S.A. and Subsidiaries**

Interim consolidated financial statements as of June 30, 2021 and December 31, 2020 and for the six-month period ended June 30, 2021 and 2020.

## **Contents**

### **Interim consolidated financial statements**

Interim consolidated statements of financial position

Interim consolidated income statements

Interim consolidated statements of comprehensive income

Interim consolidated statements of changes in equity

Interim consolidated statements of cash flows

Notes to the interim consolidated financial statements

## InRetail Pharma S.A. and Subsidiaries

### Interim consolidated statements of financial position

As of June 30, 2021 (unaudited) and December 31, 2020 (audited)

	Note	2021 S/(000)	2020 S/(000)		Note	2021 S/(000)	2020 S/(000)
<b>Assets</b>				<b>Liabilities and equity</b>			
<b>Current assets</b>				<b>Current liabilities</b>			
Cash and short-term deposits	4	531,443	550,113	Trade payables	11	1,861,306	1,593,595
Trade receivables, net	5	571,582	523,091	Other payables		265,258	256,787
Other receivables, net		64,876	59,411	Accounts payable to related parties	19(b)	16,681	4,081
Accounts receivables from related parties	19(b)	7,266	7,935	Interest-bearing loans and borrowings	13	131,426	189,871
Inventories, net	6	1,367,256	1,186,698	Lease liability	12(c)	199,873	159,650
Taxes recoverable		130,922	99,022	Current income tax	14(b)	2,949	72,855
Prepayments		9,154	4,595	<b>Total current liabilities</b>		<b>2,477,493</b>	<b>2,276,839</b>
<b>Total current assets</b>		<b>2,682,499</b>	<b>2,430,865</b>				
<b>Non-current assets</b>				<b>Non-current liabilities</b>			
Other receivables, net		34,289	29,671	Other payables		1,096	1,653
Investments at fair value through equity	7	51,351	54,061	Accounts payable to related parties	19(b)	1,363,493	-
Derivative financial instrument	8	79,150	112,273	Interest-bearing loans and borrowings	13	953,001	2,033,994
Property, furniture and equipment, net	9	579,550	570,506	Lease liability	12(c)	428,497	448,648
Right-of-use assets, net	12(b)	578,127	572,850	Reserves for employee retirement pension funds		23,687	21,131
Intangible assets, net	10	1,862,637	1,940,470	Deferred income tax liabilities, net	14(a)	178,218	206,516
Deferred income tax assets, net	14(a)	126,150	84,887	<b>Total non-current liabilities</b>		<b>2,947,992</b>	<b>2,711,942</b>
Other assets		7,451	7,949	<b>Total liabilities</b>		<b>5,425,485</b>	<b>4,988,781</b>
<b>Total non-current assets</b>		<b>3,318,705</b>	<b>3,372,667</b>	<b>Equity</b>			
<b>Total assets</b>		<b>6,001,204</b>	<b>5,803,532</b>	Capital stock	15(a)	15,840	15,840
				Capital premium	15(b)	482,835	482,835
				Other reserves		19,398	21,023
				Unrealized results from derivative financial instruments		(29,793)	(46,668)
				Unrealized results from valuation of investment at fair value		12,863	14,774
				Unrealized results from actuarial reserve for retirement		1,065	1,065
				Unrealized results from foreign currency translation		4,344	2,115
				Retained earnings		69,167	323,767
				<b>Total equity</b>		<b>575,719</b>	<b>814,751</b>
				<b>Total liabilities and equity</b>		<b>6,001,204</b>	<b>5,803,532</b>

The accompanying notes are an integral part of these consolidated statements.

## InRetail Pharma S.A. and Subsidiaries

### Interim consolidated Income statements

For the six-month period ended June 30, 2021 and 2020

	Note	2021 S/(000)	2020 S/(000)
Net sales of goods		3,857,714	3,246,266
Rental income		54,500	39,766
Rendering of services		97,910	96,294
<b>Revenue</b>		<b>4,010,124</b>	<b>3,382,326</b>
Cost of sales	17	(2,792,386)	(2,352,284)
<b>Gross profit</b>		<b>1,217,738</b>	<b>1,030,042</b>
Selling expenses	17	(748,245)	(632,816)
Administrative expenses	17	(139,198)	(119,875)
Other operating (expenses) income, net	1(d)	(1,267)	3,279
<b>Operating profit</b>		<b>329,028</b>	<b>280,630</b>
Financial income		2,966	6,548
Financial expenses	18	(219,301)	(95,652)
Exchange difference, net		(22,222)	(25,235)
<b>Profit before income tax</b>		<b>90,471</b>	<b>166,291</b>
Income tax expense	14(a)	(31,488)	(55,488)
<b>Net profit</b>		<b>58,983</b>	<b>110,803</b>
<b>Earnings per share:</b>			
Basic and diluted profit for the period	20	3.724	6.995

All items above are related to continuing operations.

The accompanying notes are an integral part of these consolidated statements.

## InRetail Pharma S.A. and Subsidiaries

Interim consolidated statements of comprehensive income  
For the six-month period ended June 30, 2021 and 2020

	<b>2021</b>	<b>2020</b>
	S/(000)	S/(000)
<b>Profit for the period</b>	58,983	110,803
<b>Other comprehensive income</b>		
Unrealized (loss) gain on investments at fair value through equity	(2,711)	366
Income tax effect	800	(108)
<b>Total other comprehensive income from investments at fair value through equity</b>	<b>(1,911)</b>	<b>258</b>
Unrealized gain (loss) from derivative financial instrument	23,936	(42,710)
Income tax effect	(7,061)	12,600
<b>Total comprehensive income from derivative financial instruments</b>	<b>16,875</b>	<b>(30,110)</b>
Unrealized gain from foreign currency translation	2,060	1,348
<b>Total comprehensive income from foreign currency translation</b>	<b>2,060</b>	<b>1,348</b>
<b>Other comprehensive income for the period, net of income tax effects</b>	<b>17,024</b>	<b>(28,504)</b>
<b>Total comprehensive income for the period</b>	<b>76,007</b>	<b>82,299</b>

The accompanying notes are an integral part of these consolidated statements.

## InRetail Pharma S.A. and Subsidiaries

### Interim consolidated statements of change in equity

For the six-month period ended June 30, 2021 and 2020

	<b>Capital stock</b>	<b>Capital premium</b>	<b>Other reserves</b>	<b>Unrealized results from derivative financial instrument</b>	<b>Unrealized results from investment at fair value through equity</b>	<b>Unrealized results from actuarial reserve for retirement</b>	<b>Unrealized results from foreign currency translation</b>	<b>Retained earnings</b>	<b>Total equity</b>
	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)
<b>Balance as of January 1, 2020</b>	<b>15,840</b>	<b>482,835</b>	<b>2,449</b>	<b>(3,373)</b>	<b>8,692</b>	<b>477</b>	<b>(239)</b>	<b>269,819</b>	<b>776,500</b>
Profit for the period	-	-	-	-	-	-	-	110,803	110,803
Other comprehensive income	-	-	-	(30,110)	258	-	1,348	-	(28,504)
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(30,110)</b>	<b>258</b>	<b>-</b>	<b>1,348</b>	<b>110,803</b>	<b>82,299</b>
Dividends paid	-	-	-	-	-	-	-	(139,362)	(139,362)
Transfer to other reserve	-	-	1,252	-	-	-	-	(1,252)	-
<b>Balance as of June 30, 2020</b>	<b>15,840</b>	<b>482,835</b>	<b>3,701</b>	<b>(33,483)</b>	<b>8,950</b>	<b>477</b>	<b>1,109</b>	<b>240,008</b>	<b>719,437</b>
<b>Balance as of January 1, 2021</b>	<b>15,840</b>	<b>482,835</b>	<b>21,023</b>	<b>(46,668)</b>	<b>14,774</b>	<b>1,065</b>	<b>2,115</b>	<b>323,767</b>	<b>814,751</b>
Profit for the period	-	-	-	-	-	-	-	58,983	58,983
Other comprehensive income	-	-	-	16,875	(1,911)	-	2,060	-	17,024
<b>Total comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>16,875</b>	<b>(1,911)</b>	<b>-</b>	<b>2,060</b>	<b>58,983</b>	<b>76,007</b>
Dividends paid	-	-	-	-	-	-	-	(315,039)	(315,039)
Transfer to other reserve	-	-	2,400	-	-	-	-	(2,400)	-
Other equity change	-	-	(4,025)	-	-	-	169	3,856	-
<b>Balance as of June 30, 2021</b>	<b>15,840</b>	<b>482,835</b>	<b>19,398</b>	<b>(29,793)</b>	<b>12,863</b>	<b>1,065</b>	<b>4,344</b>	<b>69,167</b>	<b>575,719</b>

The accompanying notes are an integral part of these consolidated statements.

## InRetail Pharma S.A. and Subsidiaries

### Interim consolidated statements of cash flows

For the six-month period ended June 30, 2021 and 2020

	Note	2021 S/(000)	2020 S/(000)
<b>Operating activities</b>			
Revenue		3,886,488	3,352,747
Payment of goods and services to suppliers		(2,920,414)	(2,712,432)
Payment of salaries and social benefits to employees		(410,754)	(380,436)
Taxes paid		(172,059)	(89,712)
Recovery of taxes		1,713	3,800
Other payments, net		(2,755)	(13,978)
<b>Net cash flows from operating activities</b>		<b>382,219</b>	<b>159,989</b>
<b>Investing activities</b>			
Sale of subsidiary, net of cash delivered		36,792	-
Purchase of property, furniture and equipment, net of acquisitions through leasing contracts		(44,714)	(22,554)
Loans granted to related parties		-	(111,000)
Purchase and development of intangible assets		(18,125)	(6,517)
<b>Net cash flows used in investing activities</b>		<b>(26,047)</b>	<b>(140,071)</b>
<b>Financing activities</b>			
Proceeds from interest-bearing loans and borrowings, net of structuring cost		625,418	534,228
Proceeds from related entity loans		1,336,320	-
Proceeds from derivative financial instrument settlement		21,385	-
Payment of issued bonds		(1,478,000)	-
Payment of premium for advanced cancelation of senior notes		(47,530)	-
Payment of interest-bearing loans and borrowings		(307,131)	(444,308)
Payment of lease liability	12	(117,801)	(106,139)
Interest payment of lease liability	12	(22,019)	(22,989)
Payment of dividends		(315,039)	(139,362)
Interest paid		(70,445)	(62,461)
<b>Net cash flows used in financing activities</b>		<b>(374,842)</b>	<b>(241,031)</b>
Net decrease of cash and short-term deposits		(18,670)	(221,113)
<b>Cash and short-term deposits at the beginning of the period</b>		<b>550,113</b>	<b>589,253</b>
<b>Cash and short-term deposits at the end of the period</b>		<b>531,443</b>	<b>368,140</b>
<b>Non-cash transactions</b>			
Fixed assets purchased through leasing and other financial obligations		11,515	4,010
Addition of right-of-use assets		139,745	51,438

The accompanying notes are an integral part of these consolidated statements

## Notes to the interim consolidated financial statements (continued)

### InRetail Pharma S.A. and Subsidiaries

#### Notes to the interim condensed consolidated financial statements

As of June 30, 2021 and December 31, 2020 and for the six-month period ended June 30, 2021 and 2020

#### 1. Identification, business activity, reorganization process, disposal subsidiaries and pandemic

##### (a) Identification

InRetail Pharma S.A. (hereinafter “the Company”), was incorporated on August 2, 1996. As of June 30, 2021 and December 31, 2020, the Company is a subsidiary of InRetail Peru Corp. which holds 87.02 percent of the Company’s capital stock. Likewise, InRetail Perú Corp. is a subsidiary of Intercorp Retail Inc., which is one of the entities of the Intercorp Perú Group operating in Peru and abroad.

The Company’s legal address, where its administrative offices operate, is Av. Defensores del Morro N ° 1277, Chorrillos, Lima, Republic of Peru.

##### (b) Business activity

The Company and its Subsidiaries Boticas del Oriente S.A.C., Eckerd Amazonia S.A.C., Drogueria InRetail Pharma S.A.C., Farmacias Peruanas S.A.C. and Quicorp S.A. and Subsidiaries (hereinafter and together” InRetail Pharma Group”) are mainly dedicated to operating pharmacies and to the distribution of pharmaceutical products. The InRetail Pharma Group operations are concentrated in the Andean region, with its core market in Perú.

##### (c) Reorganization process

In order to present a more efficient and organized structure, during 2020 and 2019, several corporate reorganization processes were performed, which involve some subsidiaries as Drogueria InRetail Pharma S.A.C., Farmacias Peruanas S.A.C., Mifarma S.A.C. and Cifarma S.A.C.; however, considering that said subsidiaries were controlled, directly and indirectly, by the Company and/or its shareholders since previous years, such reorganization processes had no impact on the consolidated financial statements as of June 30, 2021 and December 31, 2020.

##### (d) Disposal subsidiaries

On January 22 and February 26, 2021, InRetail Pharma Group transferred 100 percent of its participation in Química Suiza Colombia S.A.S. and Cifarma S.A.C. for approximately US\$1,958,000 (equivalent to S/7,093,000) and US\$9,399,000 (equivalent to S/34,298,000), to non-related entities.

On October 5, 2020, InRetail Pharma Group sold the shareholder interest in their Bolivian subsidiary Mifarma S.A. for approximately US\$2,000,000 (equivalent to S/7,233,000), to a non-related entity.



## Notes to the interim consolidated financial statements (continued)

The following are the assets and liabilities, at the date of disposals:

	2021		2020
	Química Suiza Colombia S.A.S. S/(000)	Cifarma S.A.C. (Perú) S/(000)	Mifarma S.A. (Bolivia) S/(000)
<b>Assets</b>			
Cash and short-term deposits	2,085	2,514	1,399
Inventories	4,487	20,001	8,522
Property, furniture and equipment, net	207	10,617	809
Right-of-use-assets, net	57	16,960	891
Intangible assets, net	-	6,907	-
Other	9,533	25,475	610
	<b>16,369</b>	<b>82,474</b>	<b>12,231</b>
<b>Liabilities</b>			
Trade accounts payables	6,709	14,018	7,586
Lease liabilities	92	20,164	890
Other	5,154	6,641	2,327
	<b>11,955</b>	<b>40,823</b>	<b>10,803</b>
<b>Net value</b>	<b>4,414</b>	<b>41,651</b>	<b>1,428</b>

### e) Pandemic

In March 2020, the World Health Agency "WHO" declared the coronavirus outbreak as a pandemic. The Company and its Subsidiaries have taken all the appropriate measures to safeguard the health of workers and ensure their critical processes.

The Peruvian Government, with the determination to reduce the impact on the Peruvian economy, granted a subsidy for each worker whose labor contract does not set the term thereof or if the term is set after March 15, 2020. The subsidy was paid to the subsidiaries of the Company, on April 16, 2020 for S/1,884,000.

On January 26, 2021, the government of Peru announced new quarantine measures for the country to contain the virus, applying different measures in each region according to four different alert levels: extreme, very high, high and moderate. Measures were initially applicable for 15 days, from January 31, 2021 to February 15, 2021, but were extended to February 28, 2021. On February 24, 2021, the government of Peru announced the lifting of the quarantine measures in the country from March 1, 2021 to March 14, 2021.

On February 24, 2021, the government of Peru announced the lifting of the quarantine measures in the country from March 1, 2021 to March 14, 2021. During this period, all shopping centers were allowed to operate both essential and non-essential retail, but with restrictions on maximum visitor capacity between 20% and 60% which varied depending on the tenant and risk level in each region.

On April 14, 2021, the government of Peru announced that, due to an increase in infections, several regions of the country would return to the level of extreme risk, where the allowed capacity in shopping centers will be 20% that will govern from April 19 to May 5, 2021.

These restrictions do not affect essential activities such as the supply of pharmaceutical products.

The Company's Management and its subsidiaries estimate that the pandemic will not have a significant impact on the consolidated financial statements.

The accompanying interim consolidated financial statements as of June 30, 2021 and 2020 were approved by the Board of Directors on August 12, 2021.

## Notes to the interim consolidated financial statements (continued)

### 2. Subsidiary activities

The Company and its Subsidiaries (hereinafter the "InRetail Pharma Group") are dedicated to the commercialization, manufacturing, distribution and marketing, nationally and internationally, of pharmaceutical products, cosmetics, food for medical use and other foods intended for protection and recovery of health through its "Inkafarma and Mifarma" pharmacy chains. The company and its subsidiaries operate 2,198 stores as of June 30, 2021 (2,165 stores as of December 31, 2020) and have operations in Peru, Ecuador and Bolivia as of June 30, 2021 (Peru, Colombia, Ecuador and Bolivia as of December 31, 2020).

The description of the activities of the main Subsidiaries of the Company are as follows:

- (a) Eckerd Amazonia S.A.C. was incorporated and started its activities in September 2001. It is dedicated to the commercialization of pharmaceutical products, cosmetic products, food for medical use and other elements aimed for health protection and recovery through its "Inkafarma" pharmacy chain. This Subsidiary's legal address is Alfonso Ugarte Avenue 1283, Loreto, Iquitos, Peru.
- (b) Boticas del Oriente S.A.C. was incorporated and started its activities in December 2007. It is dedicated to the commercialization of pharmaceutical products, cosmetic products, food for medical use and other elements aimed for health protection and recovery through its "Inkafarma" pharmacy chain. This Subsidiary's legal address is Alfonso Ugarte Avenue 1283, Loreto, Iquitos, Peru.
- (c) Droguería Pharma S.A.C. began operations in August 2020. Its economic activity is the purchase and wholesale of pharmaceutical products, personal care and other products for the protection and recovery of health.
- (d) Farmacias Peruanas S.A.C. started operations in August 2020. Its economic activity is to provide business, administrative and logistical services for the companies of the Pharma group.
- (e) Quicorp S.A. is a Holding incorporated in Peru in September 2010, and maintains 100 percent the assets of Química Suiza Comercial S.A.C. which in turn maintains 100 percent of the equity of the following Companies:
  - i. Química Suiza S.A.C.  
It was incorporated in Peru on March 6, 1939 and its legal address is located at Av. República de Panamá N° 2577, Lima, Peru.  
  
It is dedicated to the import, representation, and commercialization of pharmaceutical, food, cosmetic and, chemical nationwide, as well as other consumer products in general. In addition, it receives commissions for acting as broker in the sale of raw materials for foreign suppliers and income from various service provision.
  - ii. Cifarma S.A.C.  
It was incorporated in Peru on July 1, 1992. It is a Subsidiary of Quicorp S.A., product of the spin-off approved on May 1, 2019, who owns 99.99% of its share capital. Until April 30, 2019, it was a subsidiary of Química Suiza S.A.C. and up to September 30, 2010, Cifarma S.A.C. was a Subsidiary of Roxilan S.A., a company incorporated in Switzerland, which owned 71.96% of its capital. The registered office of Cifarma S.A. is located at Carretera Central Km. 3 N° 1315 Santa Anita, Lima, Perú.

## Notes to the interim consolidated financial statements (continued)

Cifarma S.A.C. provides services related to manufacturing and packaging of pharmaceutical, cosmetic and chemical products, with Química Suiza S.A.C. as its main client.

In February 2021, Cifarma S.A.C., was sold to an unrelated third party, the amount of the sale was S/34,298,000. See Note 1 (d).

iii. Mifarma S.A.C.

Is a Subsidiary of Quicorp S.A., product of the spin-off approved on May 1, 2019, who owns 99.99% of its capital. It was incorporated on November 22, 2005. Until April 30, 2019, it was a subsidiary of Química Suiza S.A.C. The registered office is located at Calle Víctor Alzamora N° 147, Urb. Santa Catalina, Lima, Perú.

It is dedicated to wholesale and retail of pharmaceutical, cosmetic, perfumery, toilet, hygiene and personal care and other products for health protection and recovery.

At the General Shareholders' Meeting held on March 15, 2018, the merger of the Company with Farmacias Peruanas S.A. was agreed, in which Mifarma would act as the acquiring company, therefore Farmacias Peruanas S.A. would be extinguished without the need to be dissolved or liquidated.

At the General Shareholders' Meeting held on March 31, 2018, it was agreed to reduce the share capital by S/4,818,000 corresponding to the stake of La Fiduciaria S.A. through a payment of S/11,599,128, equivalent to the equity value of its stake.

iv. Mifarma S.A.

It was incorporated in La Paz, Bolivia on March 12, 2010. It is dedicated to the import, export, purchase, sale, production, by itself or third parties, and trade of all pharmaceutical and medical products in general belonging to local and foreign companies it represents.

In October 2020, Mifarma Bolivia, which operated 23 pharmacies, was sold to an unrelated third party, the amount of the sale was S/7,233,000. See Note 1 (d).

v. Vanttive S.A.C.

It was incorporated in Peru on July 11, 2012. It is a direct Subsidiary of Quimica Suiza S.A.C., a company incorporated in Peru, which owns 99.99% of its capital stock as of June 30, 2021 and December 31, 2020. The registered office is located at Av. República de Panamá N°2577, La Victoria, Lima.

It is dedicated to wholesale and retail, storage, distribution, counter sale, and manufacture of health natural and pharmaceutical products, specifically for patients subject to cancer treatment.

Furthermore, it may provide services like medical centers under the category of doctor's office with the purpose of prevention, promotion, diagnosis, medical treatment, and rehabilitation in order to keep people healthy.

## Notes to the interim consolidated financial statements (continued)

- vi. Quifatex S.A.  
It was incorporated on May 26, 1978 in the city of Quito, Ecuador. The registered office is located at Av. 10 de Agosto 10640 y Manuel Zambrano, Quito, Ecuador. It is controlled and supervised by the Superintendence of Corporations in the Republic of Ecuador.
- It is dedicated to the commercialization, distribution, representation, import, and export of pharmaceutical, nutrition, chemical, cosmetic, food, veterinary, insecticidal, fertilizing and liquor products, and well as tools and machinery in general.
- vii. Vanttive Cía. Ltda.  
It was incorporated on July 17, 2003 in the city of Quito, Ecuador. The registered office is located at Av. 10 de Agosto 10640 y Manuel Zambrano, Quito, Ecuador. It is controlled and supervised by the Superintendence of Corporations in the Republic of Ecuador.
- It is dedicated to the import, export, commercialization, distribution, and intermediation of specialized pharmaceutical products.
- viii. Quimiza Ltda.  
It was incorporated on August 26, 1978. It is a distributor in the cities of Tarija, Oruro, and Potosí, as well as a distribution center in Santa Cruz, Bolivia. In addition, it has offices, agencies, and branches in other districts of the country. Currently, it has four offices in the cities of Santa Cruz (main office), La Paz, Cochabamba, and Sucre.
- It is dedicated to the manufacture, commercialization, distribution, import, export, and representation of chemical, pharmaceutical, dietary, veterinary, cosmetic, insecticidal and fertilizing products, as well as machinery and equipment for the industry and consumables in general. Currently, it imports and commercializes pharmaceutical, industrial, consumption and veterinary products, expanding its market by signing new representation agreements.
- ix. Quimica Suiza Colombia S.A.S. (Formerly Quideca S.A.)  
It was incorporated on March 13, 2006 in Bogota, Colombia and is legally effective up to March 13, 2056.
- It is dedicated to the purchase, sale, commercialization, promotion, distribution, representation, import, and export of health and pharmaceutical products, including vaccines, food, cosmetic, hygiene, personal care and home products. It also trades pesticides, herbicides, insecticides, fertilizers, chemical and agrochemical products, construction additives, tools, and equipment.
- In January 2021, Quimica Suiza Colombia S.A.S., was sold to an unrelated third party, the amount of the sale was S/7,093,000. See Note 1 (d).
- x. Albis S.A.C.  
Is a private legal entity incorporated in 1998 as a result of the merger of Distribuidora Albis S.A. with Albis Data S.A.
- It is dedicated to the commercialization of pharmaceutical, cosmetic, perfumery, toilet, hygiene and personal care and other products for health protection and recovery, nationwide.

## Notes to the interim consolidated financial statements (continued)

At the General Shareholders Meeting, of August 1, 2019, of Albis S.A.C. and Cifarma S.A.C. The reorganization of both companies was approved, through this reorganization, Albis S.A.C. segregates and transfers an equity block to Cifarma S.A.C. composed of assets and liabilities related to the laboratory business. The net value of the equity block is S/9,555,163, which was contributed to Cifarma S.A.C.

- xi. Jorsa de la Selva S.A.C.  
Is a legal entity, Subsidiary of Albis S.A.C., mainly dedicated to the commercialization of pharmaceutical, cosmetic, perfumery, toilet, hygiene, personal care and other products for health protection and recovery. The Company's legal address is located at Av. Elías Aguirre 1107, Loreto, Perú.

### 3. Basis of preparation and presentation, changes in the accounting policies of the Pharma group

#### (a) Interim financial statements

The consolidated financial statements of the InRetail Pharma Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Boards (IASB), effective as of June 30, 2021 and December 31, 2020, respectively.

The interim financial statements of the InRetail Pharma Group have been prepared in accordance with IAS 34 "Interim Financial Reporting".

The interim financial information does not include all the information and disclosures required in the annual financial statements and should be read in conjunction with the audited annual information.

The consolidated financial statements have been prepared on a historical cost basis, except for financial instruments at fair value through profit and loss, financial instruments at fair value through other comprehensive income and derivative financial instruments. The consolidated financial statements are presented in Soles and all values are rounded to the nearest thousand (S/(000)), except when otherwise indicated.

The functional currency of the subsidiaries domiciled in Ecuador, Bolivia and Colombia are the local currency in those countries. These currencies do not belong to hyperinflationary economies. All transactions are measured in the functional currency.

## Notes to the interim consolidated financial statements (continued)

The result and the financial position of all the Group companies (none of which has the currency for a hyperinflationary economy), that have a functional currency other than the InRetail Pharma S.A.'s presentation currency are translated into the presentation currency as follows:

- Assets and liabilities for each statement of financial position presented (including comparatives) shall be translated at the closing exchange rate at the date of the statement of financial position;
- Income and expenses for each statement presenting profit or loss and other comprehensive income (including comparatives) shall be translated at the average exchange rates for the corresponding year;
- Equity accounts shall be translated at the exchange rates at the date of the transactions; and
- All resulting exchange differences shall be recognized in other comprehensive income as profit or loss on translation.

At the date of this report, all the entities consolidated into the accompanying financial statements are legal subsidiaries of InRetail Pharma S.A.

### (b) Basis of consolidation

The consolidated financial statements comprise the financial statements of the Company and its subsidiaries, see Note 2.

Subsidiaries are fully consolidated from the date of acquisition, being the date on which the InRetail Pharma Group obtains control, and continues to be consolidated until the date when such control ceases. The financial statements of the subsidiaries are prepared for the same period as the parent company, using consistent accounting policies. All intra-group balances, transactions, unrealized gains and losses resulting from intra-group transactions and dividends are eliminated in full.

The non-controlling interests have been determined in proportion to the participation of minority shareholders in the net equity and the results of the subsidiaries in which they hold shares, and they are presented separately in the consolidated statement of financial position and the consolidated statement of comprehensive income.

Losses in a subsidiary are attributed to the non-controlling interest even if that results in a deficit balance. A change in the ownership interest of the subsidiary, without a loss of control, is accounted as an equity transaction.

The accounting policies followed in the preparation of the consolidated financial statements are consistent with those followed in the preparation of the consolidated financial statements as of December 31, 2020.

### (c) New accounting standards

The accounting policies adopted in the preparation of the interim combined financial statements are consistent with those followed in the preparation of the Companies annual combined financial statements for the year ended December 31, 2020, except for the adoption of the new standards and interpretations as of January 1, 2020.

## Notes to the interim consolidated financial statements (continued)

The standards and amendments, and improvements to the standards that are issued, and effective up to the date of issuance of the accompanying consolidated financial statements, are disclosed below:

(i) Amendments to IFRS 3 “Business combinations”: Reference to the Conceptual Framework

In May 2020, the IASB issued Amendments to IFRS 3, intended to replace a reference to the Framework for the Preparation and Presentation of Financial Statements, issued in 1989 with a reference to the Conceptual Framework for Financial Reporting issued in March 2018 without significantly changing its requirements. The Board also added an exception to the recognition principle of IFRS 3 to avoid the issue of potential ‘Day 2’ gain or losses arising for liabilities and contingent liabilities that would be within the scope of IAS 37 or IFRIC 21 “Levies”, if uncured separately.

At the same time, the Board decided to clarify existing guidance in IFRS 3 for contingent assets that would not be affected by replacing the reference to the Framework for the Preparation and Presentation of Financial Statements. The amendments are effective for annual reporting periods beginning on or after January 1, 2022 and apply prospectively.

Since the amendments apply prospectively to transactions or other events that occur on or after the date of the first application, the InRetail Group will not be affected by these amendments on transition.

(ii) Modifications to IAS 1 “Presentation of financial statements” Classification of Liabilities as Current or Non-current

In January 2020, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The amendments clarify: (i) what is meant by a right to defer settlement; (ii) that a right to defer must exist at the end of the reporting period; (iii) that classification is unaffected by the likelihood that an entity will exercise its deferral right; and, (iv) that only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification. The amendments are effective for annual reporting periods beginning on or after January 1, 2023 and must be applied retrospectively.

The InRetail Pharma Group is currently assessing the impact the amendments will have on current practice and whether existing loan agreements may require renegotiation.

(iii) Amendments to IAS 16 “Property, plant and equipment”: Proceeds before intended Use

In May 2020, the IASB issued amendments to IAS 16, which prohibits entities deducting from the cost of an item of property, plant and equipment, any proceeds from selling items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognizes the proceeds from selling such items, and the costs of producing those items, in profit or loss. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 and must be applied retrospectively to items of property, plant and equipment made available for use on or after the beginning of the earliest period presented when the entity first applies the amendment.

The amendments are not expected to have a material impact on the InRetail Pharma Group.

## Notes to the interim consolidated financial statements (continued)

- (iv) Amendments to IAS 37 “Provisions, contingent liabilities and contingent assets”: Onerous Contracts – Costs of Fulfilling a Contract

In May 2020, the IASB issued amendments to IAS 37 to specify which costs an entity needs to include when assessing whether a contract is onerous or loss-making. The amendments apply a “directly related cost approach”. The costs that relate directly to a contract to provide goods or services include both incremental costs and an allocation of costs directly related to contract activities. General and administrative costs do not relate directly to a contract and are excluded unless they are explicitly chargeable to the counterparty under the contract. The amendments are effective for annual reporting periods beginning on or after January 1, 2022.

The InRetail Group will apply these amendments to contracts for which it has not yet fulfilled all its obligations at the beginning of the annual reporting period in which it first applies the amendments.

- (v) Annual Improvements (2018-2020 cycle)

As part of its 2018-2020 annual improvement to IFRS standards process, the IASB issued the following amendments:

- IFRS 1 “First-time adoption of international financial reporting standards”: Subsidiary as a first-time adopter

The amendment permits a subsidiary that elects to apply paragraph D16(a) of IFRS1 to measure cumulative translation differences using the amounts reported by the parent, based on the parent’s date of transition to IFRS. This amendment is also applied to an associate or joint venture that elects to apply paragraph D16(a) of IFRS 1. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 with earlier adoption permitted.

- IFRS 9 “Financial instruments”: Fees in the ‘10 percent’ test for derecognition of financial liabilities

The amendment clarifies the fees that an entity includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. These fees include only those paid or received between the borrower and the lender, including fees paid or received by either the borrower or lender on the other’s behalf. An entity applies the amendment to financial liabilities that are modified or exchanged on or after the beginning of the annual reporting period in which the entity first applies the amendment. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 with earlier adoption permitted.

- IAS 41 “Agriculture”: Taxation in fair value measurements

The amendment removes the requirement in paragraph 22 of IAS 41 that entities exclude cash flows for taxation when measuring the fair value of assets within the scope of IAS 41. An entity applies the amendment prospectively to fair value measurements on or after the beginning of the first annual reporting period beginning on or after January 1, 2022 with earlier adoption permitted.

In the Management's opinion, these standards will not have a significant impact on the consolidated financial statements of the InRetail Pharma Group.



## Notes to the interim consolidated financial statements (continued)

### 4. Cash and short-term deposits

(a) The table below presents the components of this account:

	As of June 30, 2021 S/(000)	As of December 31, 2020 S/(000)
Cash (b)	8,573	6,186
Current accounts (c)	476,440	507,495
Time deposits (d)	101	639
Cash in transit	46,329	35,793
<b>Total</b>	<b>531,443</b>	<b>550,113</b>

(b) Comprises mainly cash held by subsidiaries in the premises of their store chains and in the vaults of a security company, corresponding to sales during the last days of the period.

(c) The company and its Subsidiaries maintain current accounts in local banks in the currency of each country and US Dollars. They do not accrue interest and are freely available.

(d) As of June 30, 2021, the time deposits are freely available and are kept in Soles in local banks, have maturities up to one month since inception and bear annual interest rates of 2.00 percent annually in US Dollars (between 1.50 and 1.62 percent annually in Colombian pesos as of December 31, 2020).

### 5. Trade receivables, net

(a) The table below presents the components of this caption:

	As of June 30, 2021 S/(000)	As of December 31, 2020 S/(000)
Trade accounts receivable (b)	602,737	558,690
Credit card operators (c)	21,360	13,145
<b>Total</b>	<b>624,097</b>	<b>571,835</b>
Provision for doubtful accounts (d)	(52,515)	(48,744)
<b>Total</b>	<b>571,582</b>	<b>523,091</b>

(b) Trade receivables are denominated in the currency of each country and US Dollars, have current maturity and do not bear interest.

(c) Corresponds mainly to pending deposits in favor of InRetail Pharma Group for the last days of the month, held by credit card operators and originated from the sale of goods with credit cards in the different stores of InRetail Pharma Group.

## Notes to the interim consolidated financial statements (continued)

- (d) The movement in the provision for doubtful accounts receivables for the six-month period ended June 30, 2021 and 2020, were as follows:

	<b>2021</b> S/(000)	<b>2020</b> S/(000)
<b>Balance at the beginning of the period</b>	<b>48,744</b>	<b>44,734</b>
Provision recognized as expense, Note 17 (a)	5,214	2,932
Recoveries, Note 17 (a)	(1,068)	(571)
Write-offs	(1,079)	(265)
Foreign currency translation	1,440	309
Others	(736)	949
<b>Balance at the end of the period</b>	<b>52,515</b>	<b>48,088</b>
<b>Balance as of December 31, 2020</b>		<b>48,744</b>

As of June 30, 2021 and December 31, 2020, the amount of overdue account receivables but non-impaired amounted to approximately S/102,767,000 and S/86,504,000, respectively.

In the opinion of Management of the InRetail Pharma Group, the provision for doubtful accounts receivables as of June 30, 2021 and December 31, 2020, appropriately covers the credit risk of this item at those dates.

### 6. Inventories, net

- (a) The composition of this item is presented below:

	<b>As of June 30, 2021</b> S/(000)	<b>As of December 31, 2020</b> S/(000)
Goods, Note 17 (a)	1,270,500	1,091,368
In transit inventories (b)	113,105	87,023
Raw material, Note 17 (a)	-	19,552
Miscellaneous supplies	4,641	3,393
Miscellaneous supplies for manufacturing, Note 17 (a)	458	550
Finished goods, Note 17 (a)	-	455
<b>Total</b>	<b>1,388,704</b>	<b>1,202,341</b>
<b>Minus</b>		
Provision for impairment of inventories (c)	(21,448)	(15,643)
<b>Total</b>	<b>1,367,256</b>	<b>1,186,698</b>

- (b) Corresponds to goods and miscellaneous supplies imported by the Company and its Subsidiaries in order to satisfy customers' demand in its pharmacies.

## Notes to the interim consolidated financial statements (continued)

(c) The movement in the provision for inventory impairment for the six-month period ended June 30, 2021 and 2020, were as follows:

	<b>2021</b> S/(000)	<b>2020</b> S/(000)
<b>Balance at the beginning of the period</b>	<b>15,643</b>	<b>12,525</b>
Provision of the period, Note 17 (a)	12,017	11,653
Recovery	(4,146)	(51)
Write-off	(2,213)	-
Foreign currency translation	147	205
<b>Balance at the end of the period</b>	<b>21,448</b>	<b>24,332</b>
<b>Balance as of December 31, 2020</b>		<b>15,643</b>

The provision for inventory impairment is determined based on stock turnover, discounts granted for the liquidation of the merchandise and other characteristics based on periodic evaluations performed by the Management of the Company and its Subsidiaries.

### 7. Investment at fair value through equity

As of June 30, 2021, the Company has other investments at fair value through equity for an amount of US\$13,341,000 equivalent to S/51,351,000 (US\$14,942,000 equivalent to S/54,061,000 as of December 31, 2020).

The fair value of these instruments is determined by the price quotes published in an active market.

As of June 30, 2021 and December 31, 2020, the unrealized result net of deferred tax is S/12,863,000 and S/14,774,000 respectively and is presented in the consolidated statement of changes in equity.

### 8. Derivative financial instrument

As of June 30, 2021 and December 31, 2020, this item comprises of a principal Call Spread. The Call Spread contract was designated to hedge cash flows and was recorded at its fair value. The detail of this operation is as follows:

<b>Counterparty</b>	<b>Nominal value</b> US\$(000)	<b>Due</b>	<b>Book value of the hedged item</b> S/(000)	<b>Fair value 2021</b> S/(000)	<b>Fair value 2020</b> S/(000)
Citibank N.A. (a)	400,000	May-23	1,449,600	-	112,273
Citibank N.A. (b)	288,000	Mar-28	1,113,408	79,150	-
<b>Total</b>				<b>79,150</b>	<b>112,273</b>

## Notes to the interim consolidated financial statements (continued)

- (a) In March 2021, InRetail Pharma settled the Call Spread early, which maturity was in May 2023 and which hedged the issuance of senior notes by InRetail Pharma up to a value of US\$400,000,000 (see note 13(b)). The early settlement of the derivative included the settlement of the liability created by the financing received from Citibank N.A. for the acquisition of the derivative; as of December 31, 2020, the value of said liability amounted to around US\$9,874,000 (equivalent to around S/35,785,000) (see note 13). As a result of this transaction, a total net expense of S/70,141,000 was generated, which is presented as "Financial expenses from the early settlement of call spread" in the consolidated income statement; see note 18.
- (b) In March 2021, InRetail Pharma S.A., decided to hedge the foreign currency exposure of its US\$288,000,000, Intercompany loan with InRetail Consumer (a related Special Purpose Entity) through a Call Spread structure, see note 19 (c).

As of June 30, 2021, this instrument covers 100 percent of the exposure in foreign currency of the principal and protects exchange rate variations between S/3.70 and S/4.20 per US\$1.00.

## Notes to the interim consolidated financial statements (continued)

### 9. Property, furniture and equipment, net

(a) The table below presents the movement and composition of this caption:

	Land	Building infrastructure and facilities	Furniture and fixture	Vehicles	Miscellaneous equipment	Work in progress	Total 2021	Total 2020
	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)	S/(000)
<b>Cost</b>								
<b>Initial balance</b>	<b>257,346</b>	<b>405,422</b>	<b>142,122</b>	<b>1,503</b>	<b>364,326</b>	<b>12,914</b>	<b>1,183,633</b>	<b>1,129,159</b>
Additions (b)	-	15,999	6,711	132	18,810	14,577	56,229	78,446
Sales (c)	-	(10)	(941)	-	(1,427)	-	(2,378)	(12,371)
Disposal (c)	-	(960)	(517)	-	(1,979)	-	(3,456)	(12,500)
Disposal of subsidiaries	(27)	(3,112)	(3,616)	(89)	(47,511)	(479)	(54,834)	(4,145)
Transfer	-	5,309	4,190	-	1,419	(10,918)	-	-
Transfer to intangible assets, Note 10(a)	-	-	-	-	-	-	-	(271)
Foreign currency translation	-	328	682	(3)	2,051	749	3,807	5,315
<b>Final balance</b>	<b>257,319</b>	<b>422,976</b>	<b>148,631</b>	<b>1,543</b>	<b>335,689</b>	<b>16,843</b>	<b>1,183,001</b>	<b>1,183,633</b>
<b>Accumulated depreciation</b>								
<b>Initial balance</b>	-	<b>238,269</b>	<b>104,508</b>	<b>1,278</b>	<b>269,072</b>	-	<b>613,127</b>	<b>568,466</b>
Additions (d)	-	15,123	4,771	88	16,176	-	36,158	66,832
Sales (c)	-	(7)	(884)	-	(1,400)	-	(2,291)	(12,215)
Disposal (c)	-	(621)	(452)	-	(1,743)	-	(2,816)	(10,628)
Disposal of subsidiaries	-	(2,557)	(3,234)	(89)	(38,130)	-	(44,010)	(3,336)
Foreign currency translation	-	207	599	(3)	2,480	-	3,283	4,008
<b>Final balance</b>	-	<b>250,414</b>	<b>105,308</b>	<b>1,274</b>	<b>246,455</b>	-	<b>603,451</b>	<b>613,127</b>
<b>Net book value</b>	<b>257,319</b>	<b>172,562</b>	<b>43,323</b>	<b>269</b>	<b>89,234</b>	<b>16,843</b>	<b>579,550</b>	<b>570,506</b>

(b) Additions for the six-month period ended June 30, 2021 and December 31, 2020, correspond mainly to the construction and equipment of new premises for InRetail Pharma Group.

(c) It mainly corresponds to assets sold and to the disposals of unused assets as a result of the process of change of format in some premises and closing of pharmacies. The resulting income or expense has been included in the "Other operating income (expenses) net" of the consolidated income statement, respectively.

## Notes to the interim consolidated financial statements (continued)

- (d) Depreciation expense for the six-month period ended June 30, 2021 and 2020, was recorded as follows in the income statement:

	2021 S/(000)	2020 S/(000)
Sales expenses, Note 17 (a)	31,734	25,014
Administrative expenses, Note 17 (a)	3,449	3,207
Cost of sales, Note 17 (a)	975	2,928
<b>Balance as of June 30</b>	<b>36,158</b>	<b>31,149</b>
<b>Balance as of December 31, 2020</b>		<b>66,832</b>

- (e) As of June 30, 2021, the cost and corresponding accumulated depreciation of assets acquired through financial leases amount to approximately S/85,212,000 and S/61,586,000, respectively (S/77,094,000 and S/58,818,000, as of December 31, 2020).

- (f) The InRetail Pharma Group maintains insurance policies on their main assets in accordance with the policies established by Management.

### 10. Intangible assets, net

- (a) The table below presents the movement and composition of this caption:

	As of June 30, 2021 S/(000)	As of December 31, 2020 S/(000)
<b>Cost</b>		
<b>Initial balance</b>	<b>867,950</b>	<b>847,734</b>
Additions (c)	18,125	23,206
Disposal and/or sales	(364)	(3,091)
Disposal of subsidiaries	(8,499)	(525)
Transfer from property, plant and equipment, Note 9 (a)	-	271
Foreign currency translation	288	355
<b>Final balance</b>	<b>877,500</b>	<b>867,950</b>
<b>Accumulated amortization</b>		
<b>Initial balance</b>	<b>200,114</b>	<b>142,356</b>
Additions (d)	89,054	58,672
Disposals and/or sales	(342)	(698)
Disposal of subsidiaries	(1,592)	(525)
Foreign currency translation	263	309
<b>Final balance</b>	<b>287,497</b>	<b>200,114</b>
<b>Goodwill</b>		
<b>Initial balance</b>	<b>1,272,634</b>	<b>1,272,634</b>
Additions	-	-
<b>Final balance</b>	<b>1,272,634</b>	<b>1,272,634</b>
<b>Net, book value</b>	<b>1,862,637</b>	<b>1,940,470</b>

## Notes to the interim consolidated financial statements (continued)

- (b) As of June 30, 2021 and December 31, 2020, this caption mainly includes the goodwill, related to the acquisition of the Quicorp Group. Purchase price for the acquisition of Quicorp was approximately US\$591,351,000 equivalent to S/1,898,255,000 at the date of acquisition.
- (c) As of June 30, 2021 and December 31, 2020, additions mainly correspond to: (i) disbursements for the acquisition of a commercial software program, a general planning system (ERP) and related licenses; and (ii) disbursements for implementation of software and licenses in new stores of InRetail Group.
- (d) Amortization expense for the six-month period ended June 30, 2021 and 2020 has been recorded in the following items of the combined statements:

	2021 S/(000)	2020 S/(000)
Sales expenses, Note 17 (a)	85,374	25,997
Administrative expenses, Note 17 (a)	3,602	2,411
Cost of sales, Note 17 (a)	78	141
<b>Balance as of June 30</b>	<b>89,054</b>	<b>28,549</b>
<b>Balance as of December 31, 2020</b>		<b>58,672</b>

### 11. Trade payables

The table below presents the composition of this caption:

	As of June 30, 2021 S/(000)	As of December 31, 2020 S/(000)
Bills payable from purchase of goods	1,700,161	1,458,088
Bills payable from commercial services	161,145	135,507
<b>Total</b>	<b>1,861,306</b>	<b>1,593,595</b>

This item mainly includes the obligations to non-related local and foreign suppliers, denominated in local currency and US Dollars, originated mainly from the acquisition of goods, with current maturities and that do not bear any interest. There have been no liens granted on these obligations.

InRetail Pharma Group offers its suppliers access to an accounts payable service arrangement provided by third party financial institutions. This service allows the suppliers to sell their receivables to the financial institutions in an arrangement separately negotiated by the supplier and the financial institution, enabling suppliers to better manage their cash flow and reduce payment processing costs. InRetail Pharma Group has no direct financial interest in these transactions. All of InRetail Pharma Group's obligations, including amounts due, remain due to its suppliers as stated in the supplier agreements.

## Notes to the interim consolidated financial statements (continued)

### 12. Leases

- a) The InRetail Pharma Group maintains leasing contracts for buildings, facilities and vehicles used for its operations. Leases of buildings and facilities generally have terms of 1 to 5 years, and leases of vehicles have terms of 3 to 4 years. The InRetail Pharma Group's obligations under its leases are guaranteed by the lessor's title of the leased assets.

There are several leases that include extension and termination options and variable payments. The InRetail Pharma Group has also entered into certain leases of premises with terms of 12 months or less and leases of low-value office equipment. The InRetail Pharma Group applies the short-term and low-value lease exemptions for this kind of leases.

- b) The movement of this caption for the six-month period ended as of June 30, 2021 and December 31, 2020, is as follows:

	<b>Buildings infrastructure and facilities</b>	<b>Vehicles</b>	<b>As of June 30, 2021</b>	<b>As of December 31, 2020</b>
	S/(000)	S/(000)	S/(000)	S/(000)
<b>Cost</b>				
<b>Initial balance</b>	<b>1,025,621</b>	<b>3,092</b>	<b>1,028,713</b>	<b>920,157</b>
Additions	139,430	315	139,745	118,334
Disposal and/or sales	(6,951)	(233)	(7,184)	(8,848)
Disposal subsidiaries	(25,459)	(109)	(25,568)	(3,271)
Foreign currency translation	3,237	171	3,408	2,341
<b>Final balance</b>	<b>1,135,878</b>	<b>3,236</b>	<b>1,139,114</b>	<b>1,028,713</b>
<b>Accumulated depreciation</b>				
<b>Initial balance</b>	<b>454,579</b>	<b>1,284</b>	<b>455,863</b>	<b>235,037</b>
Additions, Note 17 (a)	118,521	400	118,921	228,010
Disposal and/or sales	(6,336)	(233)	(6,569)	(5,995)
Disposal subsidiaries	(8,502)	(49)	(8,551)	(2,380)
Foreign currency translation	1,252	71	1,323	1,191
<b>Final balance</b>	<b>559,514</b>	<b>1,473</b>	<b>560,987</b>	<b>455,863</b>
<b>Net book value</b>	<b>576,364</b>	<b>1,763</b>	<b>578,127</b>	<b>572,850</b>

Depreciation expense for the six-month period ended June 30, 2021 and 2020, was recorded as follows in the income statement:

	<b>2021</b>	<b>2020</b>
	S/(000)	S/(000)
Sales expenses, Note 17 (a)	114,393	111,195
Administrative expenses, Note 17 (a)	2,949	1,947
Cost of sales, Note 17 (a)	1,579	2,593
<b>Balance as of June 30</b>	<b>118,921</b>	<b>115,735</b>
<b>Balance as of December 31, 2020</b>		<b>228,010</b>



## Notes to the interim consolidated financial statements (continued)

- c) The movement of the lease liability caption, as of June 30, 2021 and December 31, 2020, is as follows:

	<b>As of June 30, 2021</b>	<b>As of December 31, 2020</b>
	S(000)	S(000)
<b>Initial balance</b>	<b>608,298</b>	<b>671,189</b>
Additions	139,745	118,334
Increase for accrued interest, Note 18	22,019	44,137
Amortization	(139,800)	(256,206)
Disbursements made at the start of the contract	(20)	(4,338)
Disposal	(714)	(2,900)
Disposal subsidiary	(20,256)	(890)
Prepayment rents	(1,041)	286
Exchange rate	18,052	37,501
Foreign currency translation	2,087	1,185
<b>Final balance</b>	<b>628,370</b>	<b>608,298</b>
Current	199,873	159,650
Non-current	428,497	448,648
<b>Final balance</b>	<b>628,370</b>	<b>608,298</b>

Additionally, in the six-month period ended as of June 30, 2021 and 2020, interest related to the lease liability of S/22,019,000 and S/22,989,000, respectively, was accrued and is presented under "Financial expenses" in the consolidated financial statement of income.

## Notes to the interim consolidated financial statements (continued)

### 13. Interest-bearing loans and borrowings

(a) The table below presents the composition of this caption:

Type of obligation	Original currency	Interest rate %	Final maturity	Original amount				Total		Current		Non-current	
				US\$ (000)	\$ (000)	S/(000)	B\$(000)	2021 S/(000)	2020 S/(000)	2021 S/(000)	2020 S/(000)	2021 S/(000)	2020 S/(000)
<b>Senior Notes Unsecured (b)</b>													
Senior Notes Unsecured	PEN	6.438	2025	-	-	385,800	-	384,226	384,041	-	-	384,226	384,041
Senior Notes Unsecured	USD	5.375	2023	400,000	-	-	-	-	1,436,872	-	-	-	1,436,872
				<b>400,000</b>	-	<b>385,800</b>	-	<b>384,226</b>	<b>1,820,913</b>	-	-	<b>384,226</b>	<b>1,820,913</b>
<b>Leasings</b>													
<b>Non related entities</b>													
Banco Santander	PEN	7.650	2022	-	-	874	-	234	328	199	192	35	136
Banco Santander	PEN	6.920	2022	-	-	545	-	225	316	192	186	33	130
BBVA Banco Continental	PEN	4.950	2021	-	-	129	-	-	19	-	19	-	-
				-	-	<b>1,548</b>	-	<b>459</b>	<b>663</b>	<b>391</b>	<b>397</b>	<b>68</b>	<b>266</b>
<b>Notes and Loans</b>													
<b>Related entities</b>													
Banco Internacional del Perú-Interbank (g)	PEN	4.700	2025	-	-	161,950	-	-	103,363	-	22,970	-	80,393
Banco Internacional del Perú-Interbank (g)	PEN	3.750	2026	-	-	220,000	-	218,132	-	-	-	218,132	-
Banco Internacional del Perú-Interbank	PEN	0.400	2021	-	-	35,000	-	-	35,000	-	35,000	-	-
<b>Non related entities</b>													
Banco Scotiabank (c)	PEN	4.700	2025	-	-	161,950	-	-	103,380	-	22,973	-	80,407
Banco Scotiabank (c)	PEN	3.750	2026	-	-	330,000	-	327,199	-	-	-	327,199	-
Banco de Bogotá	COP	6.030	2023	-	2,900,000	-	-	-	3,061	-	1,052	-	2,009
Banco BBVA Colombia	COP	6.100	2021	-	89,968	-	-	-	94	-	94	-	-
Citibank (f)	USD	5.000	2022	10,000	-	-	-	26,849	30,203	21,479	10,068	5,370	20,135
Banco Pichincha (e)	USD	7.500	2021	300	-	-	-	1,160	1,087	1,160	1,087	-	-
Banco Scotiabank (c)	PEN	0.500	2021	-	-	15,000	-	15,000	-	15,000	-	-	-
Banco Scotiabank (c)	PEN	0.450	2021	-	-	21,000	-	21,000	-	21,000	-	-	-
Banco Scotiabank (c)	PEN	0.550	2021	-	-	15,000	-	15,000	-	15,000	-	-	-
Banco Scotiabank	PEN	0.700	2021	-	-	21,000	-	-	21,000	-	21,000	-	-
Banco de Crédito del Perú (d)	PEN	Between 0.470 and 0.590	2021	-	-	50,000	-	50,000	-	50,000	-	-	-
Banco de Crédito del Perú	PEN	1.070	2021	-	-	8,000	-	-	8,000	-	8,000	-	-
Banco de Crédito del Perú	PEN	0.820	2021	-	-	45,000	-	-	45,000	-	45,000	-	-
				<b>10,300</b>	<b>2,989,968</b>	<b>1,083,900</b>	-	<b>674,340</b>	<b>350,188</b>	<b>123,639</b>	<b>167,244</b>	<b>550,701</b>	<b>182,944</b>
<b>Call Spread financing, Note 8</b>													
Citibank N.A.	USD	6.473	2023	18,297	-	-	-	-	35,785	-	15,977	-	19,808
				<b>18,297</b>	-	-	-	-	<b>35,785</b>	-	<b>15,977</b>	-	<b>19,808</b>
<b>Other obligations (h)</b>													
Hewlett Packard S.A.	USD	Between 2.850 and 4.360	2024 and 2026	8,549	-	-	-	25,402	16,316	7,396	6,253	18,006	10,063
				<b>8,549</b>	-	-	-	<b>25,402</b>	<b>16,316</b>	<b>7,396</b>	<b>6,253</b>	<b>18,006</b>	<b>10,063</b>
<b>Total</b>				<b>437,146</b>	<b>2,989,968</b>	<b>1,471,248</b>	-	<b>1,084,427</b>	<b>2,223,865</b>	<b>131,426</b>	<b>189,871</b>	<b>953,001</b>	<b>2,033,994</b>

## Notes to the interim consolidated financial statements (continued)

- (b) In May 2018, the Company issued debt instruments ("Notes") denominated in US Dollars through a private offer to institutional investors under Rule 144 A and Regulation S, for US\$400,000,000, equivalent to S/1,449,600,000 as of December 31, 2020 that accrues an interest of 5.375 percent annual, with a maturity of 5 years and with semiannual payments of interest and the principal in a single installment upon maturity of the securities. This borrowing was recorded in the consolidated financial statement at amortized cost to an effective interest rate of 5.778 percent, after considering the respective up-front fees that amounted to US\$3,512,000 equivalent to approximately S/12,728,000 as of December 31, 2020. In March 2021, the "Senior Notes Unsecured" were prepaid in full.

As indicated in note 8 (a), the Call Spread related to these bonds was settled early in March 2021.

Additionally, in May 2018, the Company issued debt instruments ("Notes") denominated in Soles for S/385,800,000 that bear an annual interest rate of 6.438 percent, with a maturity of 7 years and with semiannual interest payments and the principal in a single installment upon maturity of the securities. This borrowing was recorded in the consolidated financial statement at amortized cost to an effective interest rate of 6.559 percent, after considering the respective up-front fees that amounted to S/1,574,000 as of June 30, 2021 (S/1,759,000 as of December 31, 2020).

As a result of these issues, InRetail Pharma must comply, until their maturity and full payment, with certain obligations and covenants.

In the opinion of Management, these covenants do not limit the operations of the Company and its Subsidiaries and have been complied satisfactorily and are within the agreed limits as of June 30, 2021 and December 31, 2020. Likewise, 100 percent of the "Senior Notes Unsecured" is guaranteed by the shares of InRetail Pharma S.A. and Subsidiaries.

- (c) Scotiabank Perú  
Química Suiza S.A.C.  
It corresponds to three loans of S/15,000,000, S/15,000,000 and S/21,000,000 with maturity in July, August and September 2021. The annual accrued interest rates are 0.45, 0.50 and 0.55 percent. There are no specific guarantees.

InRetail Pharma S.A.

It corresponds to one loan amounting of S/161,950,000. The annual accrued interest rate is 4.70 percent with maturity in April 2025, and quarterly payments. This borrowing was recorded in the consolidated financial statement at amortized cost to an effective interest rate of 4.775 percent, after considering the respective up-front fees that amounted of S/731,000 as of December 31, 2020. InRetail Pharma S.A. amortized the debt for the amount of S/57,839,000 as of December 31, 2020. In March 2021, the loan was fully paid.

In March, 2021, the company obtained a loan for S/330,000,000 that accrues an annual nominal interest of 3.750 percent maturing in March 2026, payable in quarterly installments. Said loan is recorded at its amortized cost at an effective annual rate of 4.031 percent, after considering the additional charges of S/2,801,000 as of June 30, 2021.

## Notes to the interim consolidated financial statements (continued)

- (d) Banco de Crédito del Perú  
Química Suiza S.A.C.  
Corresponds to two loans of S/20,000,000 and S/30,000,000 with maturity in August and November 2021. The annual accrued interests rate are 0.470 and 0.59 percent. There are no specific guarantees.
- (e) Banco Pichincha  
Vantive Cía Ltda.  
It corresponds to one loan amounting to US\$300,000 with maturity in November 2021. The annual accrued interest rate is 7.500 percent annual.
- (f) Citibank  
Quifatex S.A.  
It corresponds to one loan amounting to US\$10,000,000 with maturity in April 2022 and accrued interest rate of 5.000 percent annual.
- (g) Banco Internacional del Perú-Interbank  
InRetail Pharma S.A.  
Corresponds to a loan granted for S/161,950,000 that accrues an annual nominal interest of 4.70 percent, with maturity in April 2025, payable quarterly. This loan is recorded at amortized cost at an effective rate of 4.775 percent, after considering the initial charges of S/748,000 as of December 31, 2020. The Company amortized the debt for the amount of S/57,839,000 as of December 31, 2020. In March 2021, was paid fully.
- In March 2021, the company obtained a loan for S/220,000,000 that accrues an annual nominal interest of 3.750 percent maturing in March 2026, payable in quarterly installments. Said loan is recorded at its amortized cost at an effective annual rate of 4.031 percent, after considering the additional charges of S/1,868,000 as of June 30, 2021.
- (h) Corresponds to the debt acquired with Hewlett Packard S.A., for the purchase and leasing of computer equipment. These contracts do not have specific guarantees.
- (i) During the six-month period ended June 30, 2021 and 2020, loans and borrowings accrued interests are recorded in the "Financial expenses" caption of the consolidated income statement, see Note 18. Also, as of June 30, 2021 and December 31, 2020, there are interests payable which are recorded in the "Other payables" caption of the consolidated statements of financial position.
- (j) Some of the interest-bearing loans and borrowings include standard clauses requiring the InRetail Pharma Group to meet financial ratios, use of funds criteria and other administrative matters. In Management's opinion, as of June 30, 2021 and December 31, 2020, standard clauses do not limit the normal operation of the InRetail Pharma Group and have been fulfilled.

- (k) Financial obligations are payable as follows:

	<b>2021</b>	<b>2020</b>
	S/ (000)	S/ (000)
2021	117,365	189,871
2022	22,427	84,775
2023	5,784	1,492,184
2024	5,856	72,994
2025	657,708	384,041
2026 onwards	275,287	-
<b>Total</b>	<b>1,084,427</b>	<b>2,223,865</b>

## Notes to the interim consolidated financial statements (continued)

### 14. Income tax

- (a) The amounts presented in the statement of financial position as of June 30, 2021 and December 31, 2020, as well as the consolidated income statements for the six-month period ended June 30, 2021 and 2020 are shown below:

Statements of financial position	As of June 30, 2021		As of December 31, 2020	
	Assets	Liabilities	Assets	Liabilities
	S/(000)	S/(000)	S/(000)	S/(000)
InRetail Pharma S.A.	57,888	-	25,882	-
Eckerd Amazonia S.A.C.	999	-	861	-
Boticas del Oriente S.A.C.	856	-	673	-
Química Suiza S.A.C.	-	47,667	-	48,915
Cifarma S.A.C.	-	-	852	-
Vanttive S.A.C.	64	-	46	-
Droguería InRetail Pharma S.A.C.	2,686	-	1,793	-
Quicorp S.A.	1,704	-	931	-
Quifatex S.A.	9,275	-	8,201	-
Vanttive Cia Ltda.	120	-	101	-
Farmacías Peruanas S.A.C.	3,972	-	136	-
Quimiza Ltda.	673	-	766	-
Química Suiza Colombia S.A.S. (formerly Quideca S.A.)	-	-	766	-
Mifarma S.A.C.	32,106	-	26,337	-
Albis S.A.C.	14,248	-	16,047	-
Jorsa de la Selva S.A.C.	1,559	-	1,495	-
Consolidation adjustment	-	130,551	-	157,601
<b>Total</b>	<b>126,150</b>	<b>178,218</b>	<b>84,887</b>	<b>206,516</b>

Statements of comprehensive income	Income tax for the six-month period ended June 30, 2021 and 2020	
	2021	2020
	S/(000)	S/(000)
Current	(108,219)	(78,909)
Deferred	76,731	23,421
<b>Income tax expense</b>	<b>(31,488)</b>	<b>(55,488)</b>

- (b) As of June 30, 2021 and December 31, 2020, the liability for income tax, net of the advanced tax, amounted to approximately S/2,949,000 and S/72,855,000, respectively. Also, as of June 30, 2021 and December 31, 2020, the income tax credit amounted to approximately S/70,476,000 and S/77,854,000, respectively.

### 15. Equity

- (a) Capital stock

As of June 30, 2021 and December 31, 2020, the capital stock of the Company is represented by 15,839,379 common shares, with a nominal value of S/1.00 each, which are entirely authorized and paid.

## Notes to the interim consolidated financial statements (continued)

(b) Capital Premium

Corresponds to cash contributions for a total amount of approximately S/4,182,000. In accordance with the agreements of the General Shareholders Meetings of July 2008, an amount of S/791,000 was recorded as capital stock and the difference of approximately S/3,391,000 was recorded as a capital premium, which is presented in the caption "Capital premium" in the consolidated statement of financial position.

In April 2018, the merger by absorption of IR Pharma S.A.C., generated an exchange of shares for an equity received of S/481,500,000, issuing shares of S/2,056,000 and recognizing a capital premium of S/479,444,000.

(c) Legal reserve

As of June 30, 2021 and December 31, 2020, this caption includes the legal reserve established by the Company and its Subsidiaries. As provided in the General Corporations Law, it is required that a minimum of 10 percent of distributable income for each year is transferred to a legal reserve until such reserve equals 20 percent of the capital. The legal reserve can absorb losses or be capitalized, in both cases it must be replenished. The legal reserve is appropriated when the General Shareholders' Meeting approves it.

(d) Distribution of dividends

At the General Shareholders' Meeting of InRetail Pharma S.A. held on April 30, 2021, the distribution of dividends was approved for a value of S/315,000,000, which was paid on May 3, 2021.

At the General Shareholders' Meeting of InRetail Pharma S.A. held in February 2021, dividend distributions for a total of S/39,000 were approved.

At the General Shareholders' Meetings of InRetail Pharma S.A. held on February 10, 2020 and April 30, 2020 it was approved, the dividend distribution of S/79,013,000 and S/60,349,000, respectively.

### 16. Tax Situation

- (a) The Company and its Subsidiaries domiciled in Peru, Ecuador, Bolivia y Colombia, are subject to the tax regime of each country and calculate the income tax based on their individual financial statements. As of June 30, 2021 and December 31, 2020, the income tax rate was:

Country	%
Perú	29.5
Ecuador	25.0
Bolivia	25.0
Colombia	31.0

- (b) Entities and individuals not domiciled in Peru must pay an additional tax over dividends received. In this regard, attention to Legislative Decree N° 1261, the additional tax on dividend income generated is as follows:

- 4.1 percent for the profits generated until December 31, 2014.
- 6.8 percent for the profits generated in the years 2015 and 2016.
- 5.0 percent for the profits generated since January 1, 2017.

## Notes to the interim consolidated financial statements (continued)

- (c) Law No. 29663, later amended by law No. 29757, established Peruvian source income as that obtained by the indirect sales of shares representing the capital stock of companies domiciled in the country.

To this end, an indirect transference is configured when the following two assumptions occur together:

- (i) In first place, 10 percent or more of shares of the non domiciled company must be sold in a period of twelve months.
  - (ii) In second place, the market value of the Peruvian company's shares must represent 50 percent or more of the market value of the non domiciled company, in a period of twelve months.
- (d) For purposes of determining the Income Tax, transfer pricing of transactions with related companies and companies domiciled in territories with low or no taxation must be supported with documentation and information on assessment methods applied and criteria considered. Based on the analysis of the operations of the InRetail Pharma Group, Management and its legal advisors consider that as consequence of the application of the regulation in force, there will not be any significant contingencies for the InRetail Pharma Group as of June 30, 2021 and December 31, 2020.
- (e) The tax authority is legally entitled to review and, if necessary, adjust the Income Tax computed. Following are the years subject to review by the tax authority of the Subsidiaries of InRetail Pharma S.A. incorporated in Peru and foreign:

	<b>Income Tax</b>	<b>Value added tax</b>
InRetail Pharma S.A.	From 2016 to 2020	From 2017 to 2021
Eckerd Amazonía S.A.C.	From 2016 to 2020	From 2017 to 2021
Boticas del Oriente S.A.C.	From 2016 to 2020	From 2017 to 2021
Quicorp S.A.	From 2016 to 2020	From 2017 to 2021
Química Suiza Comercial S.A.C.	From 2016 to 2018	From 2017 to 2018
Vanttive S.A.C.	From 2016 to 2020	From 2017 to 2021
Vanttive Cía Ltda.	From 2016 to 2020	From 2016 to 2021
Química Suiza S.A.C.	From 2017 to 2020	From 2017 to 2021
Quifatex S.A.	From 2019 to 2020	From 2019 to 2021
Quimiza Ltda.	From 2015 to 2020	From 2015 to 2021
Jorsa de la Selva S.A.C.	From 2016 to 2020	From 2017 to 2021
Mifarma S.A.C.	From 2017 to 2020	From 2017 to 2021
Albis S.A.C.	From 2016 to 2020	From 2017 to 2021
Droguería InRetail Pharma S.A.C.	From 2019 to 2020	From 2019 to 2021
Farmacias Peruanas S.A.C.	2020	From 2020 to 2021
Botica Torres de Limatambo S.A.C.	From 2017 to 2018	From 2017 to 2018
Droguería La Victoria S.A.C.	From 2016 to 2018	From 2017 to 2018
Superfarma Mayorista S.A.C.	From 2016 to 2019	From 2016 to 2019
Farmacias Peruanas S.A.	From 2017 to 2018	From 2017 to 2018

Due to possible interpretations that the tax authority may give to legislation, it is not possible to determine, to date, whether the reviews will result in liabilities for the InRetail Pharma Group. Therefore, any major tax or surcharge that may result from eventual revisions by the tax authority would be charged to the consolidated statements of comprehensive income of the period in which such tax or surcharge is determined.

In opinion of Management of the InRetail Pharma Group as well as its legal advisor's opinion, any eventual additional tax settlement would not be significant to the consolidated financial statements as of June 30, 2021 and December 31, 2020.

## Notes to the interim consolidated financial statements (continued)

- (f) As of June 30, 2021 and December 31, 2020, estimated losses from previous periods for Subsidiaries for tax purposes are the following:

	As of June 30, 2021 S/(000)	As of December 31, 2020 S/(000)
Albis S.A.C.	26,470	39,395
InRetail Pharma S.A.	111,871	-
Quicorp S.A.	149	3,155
<b>Total</b>	<u><b>138,490</b></u>	<u><b>42,550</b></u>

According to the Income Tax Act and its amendments, entities domiciled in Peru have the faculty to choose one of the following methods to draw their tax losses:

- (i) The tax loss can be offset with future profits until its final extinction by applying said loss to up to 50 percent of the taxable income; or
- (ii) The tax loss can be used for four years after it has been generated.

Albis S.A.C. and Quicorp S.A. have chosen method (i) and InRetail Pharma S.A. the method (ii).

### 17. Operating expenses

- (a) The table below presents the components of this caption for the six-month period ended June 30, 2021 and 2020:

	2021 S/(000)	2020 S/(000)
Cost of sales	2,792,386	2,352,284
Selling expenses	748,245	632,816
Administrative expenses	139,198	119,875
<b>Total</b>	<u><b>3,679,829</b></u>	<u><b>3,104,975</b></u>

The table below presents the components of operating expenses included in cost of sales, sales and administrative expenses captions.



## Notes to the interim consolidated financial statements (continued)

	<b>2021</b>			
	<b>Cost of sales</b>	<b>Selling expenses</b>	<b>Administrative expenses</b>	<b>Total</b>
	S/(000)	S/(000)	S/(000)	S/(000)
Initial balance of goods, Note 6 (a)	1,091,368	-	-	1,091,368
Initial balance of raw material, Note 6 (a)	19,552	-	-	19,552
Initial balance of supplies, Note 6 (a)	550	-	-	550
Initial balance of finished goods, Note 6 (a)	455	-	-	455
Purchase of goods and supplies	2,917,388	-	-	2,917,388
Final balance of goods, Note 6 (a)	(1,270,500)	-	-	(1,270,500)
Final balance of raw materials, Note 6 (a)	-	-	-	-
Final balance of supplies, Note 6 (a)	(458)	-	-	(458)
Final balance of finished goods, Note 6 (a)	-	-	-	-
Impairment of inventories, Note 6 (c)	12,017	-	-	12,017
Factory overhead	4,702	-	-	4,702
Personnel expenses	-	326,644	84,110	410,754
Depreciation, Note 9 (d)	975	31,734	3,449	36,158
Depreciation of right-of-use asset, Note 12 (b)	1,579	114,393	2,949	118,921
Amortization, Note 10 (d)	78	85,374	3,602	89,054
Services provided by third parties (b)	-	120,227	31,956	152,183
Advertising	-	25,624	3	25,627
Packing and packaging	-	3,962	403	4,365
Rental of premises	-	8,215	33	8,248
Low-value asset leases	1,039	2,091	390	3,520
Taxes	-	4,577	3,903	8,480
Provision for doubtful trade receivables, Note 5(d)	-	5,153	61	5,214
Recoveries of provision trade account receivables, Note 5(d)	-	(1,068)	-	(1,068)
Recovery of provision other account receivables	-	(209)	-	(209)
Insurance	-	5,908	514	6,422
Other charges (c)	13,641	15,620	7,825	37,086
<b>Total</b>	<b>2,792,386</b>	<b>748,245</b>	<b>139,198</b>	<b>3,679,829</b>

	<b>2020</b>			
	<b>Cost of sales</b>	<b>Selling expenses</b>	<b>Administrative expenses</b>	<b>Total</b>
	S/(000)	S/(000)	S/(000)	S/(000)
Initial balance of goods	997,569	-	-	997,569
Initial balance of raw material	15,204	-	-	15,204
Initial balance of supplies	1,008	-	-	1,008
Initial balance of finished goods	189	-	-	189
Purchase of goods	2,407,682	-	-	2,407,682
Final balance of goods, Note 6(a)	(1,095,122)	-	-	(1,095,122)
Final balance of raw materials, Note 6(a)	(15,583)	-	-	(15,583)
Final balance of supplies, Note 6 (a)	(564)	-	-	(564)
Final balance of finished goods, Note 6(a)	(73)	-	-	(73)
Impairment of inventories, Note 6 (c)	11,653	-	-	11,653
Factory overhead	13,295	-	-	13,295
Personnel expenses	-	294,286	86,871	381,157
Depreciation, Note 9 (d)	2,928	25,014	3,207	31,149
Depreciation of right-of-use asset, Note 12 (b)	2,593	111,195	1,947	115,735
Amortization, Note 10 (d)	141	25,997	2,411	28,549
Services provided by third parties (b)	-	119,473	15,730	135,203
Advertising	-	18,793	-	18,793
Packing and packaging	-	5,279	59	5,338
Rental of premises	-	10,553	316	10,869
Taxes	-	4,228	2,740	6,968
Provision for doubtful trade receivables, Note 5(d)	-	2,911	21	2,932
Recovery of provision for doubtful trade receivables, Note 5(d)	-	(571)	-	(571)
Insurance	-	5,083	395	5,478
Other charges (c)	11,364	10,575	6,178	28,117
<b>Total</b>	<b>2,352,284</b>	<b>632,816</b>	<b>119,875</b>	<b>3,104,975</b>

## Notes to the interim consolidated financial statements (continued)

- (b) Corresponds mainly to expenses of electricity, water, telephone, premises maintenance services and transport services.
- (c) Mainly includes general expenses in stores.

### 18. Financial expenses

- (a) The table below presents the components of financial expenses:

	<b>2021</b>	<b>2020</b>
	S/(000)	S/(000)
Expenses for advanced settlement of "Call Spread" (e)	70,141	-
Premium for advanced cancelation of senior notes (c)	47,530	-
Interest on loans, borrowings and bonds payable	42,026	59,980
Interest on loans with related parties, Note 19 (c)	13,599	-
Interest on lease liability, Note 12 (c)	22,019	22,989
Accrual of structuring cost of financial obligation	3,235	2,602
Accrual of structuring cost of Senior Notes (d)	12,134	-
Interest from derivative instruments "Call Spread"	455	1,433
Premium accrual of "Call Spread"	5,937	6,040
Other financial expenses	2,225	2,608
<b>Total</b>	<b>219,301</b>	<b>95,652</b>

- (b) As of June 30, 2021 and December 31, 2020, there are interest payable for these obligations for approximately S/5,663,000 and S/19,087,000, respectively, which are recorded in the "Other payables" caption of the consolidated statements of financial position.
- (c) As of June 30, 2021, includes the premium corresponding to the early redemption of the "Senior Notes Unsecured" issued by InRetail Pharma S.A. in US Dollars for US\$12,794,000 equivalent to S/47,530,000.
- (d) As of June 30, 2021, corresponds mainly to the accrual of the structuring costs related to the early redemption of the "Senior Notes Unsecured" issued by InRetail Pharma S.A. in US Dollars for US\$3,284,000 equivalent to S/12,134,000.
- (e) As of June 30, 2021, it corresponds to the transfer of the value over time of other comprehensive income to income for the period, related to the early settlement of the "Call Spread". See Note 8(a).

## Notes to the interim consolidated financial statements (continued)

### 19. Transactions with related parties

(a) The following table provides the total amount of transactions that have been entered into with related parties for the six-month period ended as of June 30, 2021 and 2020:

	<b>2021</b> S/(000)	<b>2020</b> S/(000)
<b>Income</b>		
Sales	14,263	19,694
Rendering of services	1,418	764
Dividend income	973	-
Others	307	1,935
<b>Total</b>	<b>16,961</b>	<b>22,393</b>
<b>Expenses</b>		
Renting of premises and land	7,861	6,612
Reimbursement of expenses	2,630	2,899
Minor services	5,167	998
Interest	13,599	-
Others	1,708	5,061
<b>Total</b>	<b>30,965</b>	<b>15,570</b>

(b) As a result of the transactions with related companies, the InRetail Pharma Group recorded the following balances as of June 30, 2021 and December 31, 2020:

	<b>As of June 30,</b> <b>2021</b> S/(000)	<b>As of December 31,</b> <b>2020</b> S/(000)
<b>Receivables</b>		
Real Plaza S.A.	-	39
Supermercados Peruanos S.A. (e)	6,024	6,662
Homecenters Peruanos S.A. (e)	255	214
Homecenters Oriente S.A.C.	14	10
InDigital S.A.C.	7	35
Tiendas Peruanas S.A.	82	23
Financiera Oh! S.A.	551	510
InRetail Perú Corp. (f)	0	-
Makro Supermayorista S.A.	9	-
Plaza Veá Oriente S.A.C. (e)	210	181
Otros	114	261
<b>Total</b>	<b>7,266</b>	<b>7,935</b>

## Notes to the interim consolidated financial statements (continued)

	As of June 30, 2021 S/(000)	As of December 31, 2020 S/(000)
<b>Payables</b>		
Homecenters Peruanos S.A.	40	155
Financiera Oh! S.A.	950	454
InDigital S.A.C.	4	179
Real Plaza S.A.	100	272
Patrimonio Interproperties Perú	0	-
Inmobiliaria Puerta del Sol S.A.	50	99
Supermercados Peruanos S.A.	1,231	1,164
IR Management S.R.L.	133	458
InRetail Consumer (c)	1,377,122	-
Interproperties Perú	243	953
IR Digital S.A.C.	95	51
Other	206	296
<b>Total</b>	<b>1,380,174</b>	<b>4,081</b>
Remunerations payable to key management	-	-
<b>Total</b>	<b>1,380,174</b>	<b>4,081</b>

The policy of the InRetail Pharma Group is to make transactions with related companies at terms equivalent to those that prevail in arm's length transactions.

- (c) In March 2021, InRetail Consumer (Special Purpose Entity) related entity, granted a loan of US\$288,000,000 (equivalent to S/1,113,408,000 as of June 30, 2021) and S/266,400,000, said obligations were registered in the consolidated financial statements at amortized cost at an annual effective interest rate of 3.453 and 5.118 percent, respectively, after considering the respective initial charges of approximately US\$3,376,000 (equivalent to a total of approximately S/13,051,000) and S/3,264,000, respectively.

As of June 30, 2021, an interest of S/13,552,000 was accrued, which was recorded in the caption "Financial expenses" of the consolidated statement of comprehensive income. Likewise, as of June 30, 2021, accumulated interest payable of S/13,629,000 is maintained.

The funds obtained from the issues were used, mainly, for the advanced payment of the "Senior Notes Unsecured".

- (d) Outstanding balances at period-end are unsecured and interest free, except for the financial obligations explained in this note. There have been no guarantees provided or received for any related party receivables or payables. As of June 30, 2021 and December 31, 2020, the InRetail Pharma Group has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year by examining the financial position of the related party and the market in which the related party operates.
- (e) Corresponds to the balances pending for the sale of goods of Química Suiza S.A.C. as of June 30, 2021.

## Notes to the interim consolidated financial statements (continued)

- (f) The compensation of key management personnel of the InRetail Pharma Group for the six-month period ended June 30, 2021 and 2020, is detailed below:

	<b>2021</b> S/(000)	<b>2020</b> S/(000)
Short term employee benefits	14,683	16,341
Insurance and medical benefits	29	20
Employment benefits for contract termination	-	409
<b>Total</b>	<b>14,712</b>	<b>16,770</b>

- (g) As of June 30, 2021 and December 31, 2020, the InRetail Pharma Group maintains the following balances in the cash and cash equivalent captions:

	<b>2021</b> S/(000)	<b>2020</b> S/(000)
Banco Internacional del Peru – Interbank S.A.A.	240,862	338,159
Inteligo Bank Ltd.	2,017	976

## Notes to the interim consolidated financial statements (continued)

### 20. Earnings per share

Basic earnings per share amounts are calculated by dividing profit for the six-month period attributable to ordinary equity holders of InRetail Pharma S.A. by the weighted average number of ordinary shares outstanding during the same period. As there are no dilutive instruments outstanding, basic and diluted earnings per share are identical.

The following reflects basic and diluted earnings per share computations:

	<b>Ordinary shares</b>		
	<b>Outstanding shares</b>	<b>Effective days until period-end</b>	<b>Weighted average of shares</b>
Number as of January 1, 2020	15,839,379	180	15,839,379
Number as of June 30, 2020	15,839,379		15,839,379
Number as of January 1, 2021	15,839,379	180	15,839,379
Number as of June 30, 2021	15,839,379		15,839,379
	<b>For the six-months period ended June 30, 2021</b>		
	<b>Net income (numerator)</b>	<b>Shares (denominator)</b>	<b>Earnings per share</b>
	<i>S/</i>		<i>S/</i>
Basic and diluted earnings per share	58,983,000	15,839,379	3.724
	<b>For the six-months period ended June 30, 2020</b>		
	<b>Net income (numerator)</b>	<b>Shares (denominator)</b>	<b>Earnings per share</b>
	<i>S/</i>		<i>S/</i>
Basic and diluted earnings per share	110,803,000	15,839,379	6.995

There have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and the date of completion of these consolidated financial statements.

## Notes to the interim consolidated financial statements (continued)

### 21. Commitments and contingencies

Commitments –

The main commitments assumed are presented below:

- (a) As of June 30, 2021, the Company and its Subsidiaries agreed with several financial entities on the issuance of solidary and irrevocable letters of guarantee for approximately S/54,856,000, US\$1,190,000, €20,748,000 and B\$193,000 (S/53,844,000, US\$2,812,000 and B\$104,000 as of December 31, 2020), respectively, to comply with the payment of goods purchased to foreign suppliers.

Contingencies –

- (a) InRetail Pharma S.A., Albis S.A.C., Química Suiza S.A.C., Mifarma S.A.C., Jorsa de la Selva S.A.C. and Vantive S.A.C. maintain various claims for civil, labor and tax processes for an approximate total amount of S/82,674,000. In the opinion of Management and its legal advisors, said processes should be resolved favorably for these components, in opinion of Management, it is not necessary to record additional liabilities for these items as of June 30, 2021 and 2020.
- (b) Eckerd Amazonía S.A.C. is in the process of claiming against the Tax Authority for determinations of debts and fines related to VAT for the period between January 2003 and September 2005 for an approximate amount of S/17,859,000. In opinion of Management and its legal advisors these contingencies are stated as possible, and significant liabilities will not arise as result of this contingency as of June 30, 2021 and December 31, 2020.

### 22. Business segments

For management purposes, the InRetail Pharma Group is organized into business units based on their products and services and has two reportable segments as follows:

- The pharmacies segment is a nationwide supplier of drugs, medicines and cosmetic related products through the chains of pharmacies named “Inkafarma” and “Mifarma”.
- Manufacturing, Distribution and Marketing segment operates nationally and internationally.

Management monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on operating profit or loss and is measured consistently with operating profit or loss in the consolidated financial statements.

Transfer prices between operating segments are on an arm’s length basis in a manner similar to transactions with third parties.

As of June 30, 2021 and December 31, 2020, and for the six-month period ended June 30, 2021 and 2020, InRetail Pharma S.A. is organized into two main business lines. Transactions between the business segments are carried out under normal commercial terms and conditions. The following table presents the financial information of InRetail Pharma Group by business segments for the six-month period ended June 30, 2021 and 2020

	Pharmacies S/(000)	Manufacturing, Distribution and Marketing S/(000)	Total segments S/(000)	Holding accounts, consolidation adjustments and intercompany eliminations S/(000)	Consolidated S/(000)
<b>For the six-month period ended June 30, 2021</b>					
<b>Revenue</b>					
External income	2,973,768	1,036,356	4,010,124	-	4,010,124
Inter-segment	20,886	351,714	372,600	(372,600)	-
<b>Total revenue</b>	<b>2,994,654</b>	<b>1,388,070</b>	<b>4,382,724</b>	<b>(372,600)</b>	<b>4,010,124</b>
Cost of sales	(1,923,834)	(868,552)	(2,792,386)	-	(2,792,386)
Inter-segment	(14,594)	(351,853)	(366,447)	366,447	-
<b>Gross profit</b>	<b>1,056,226</b>	<b>167,665</b>	<b>1,223,891</b>	<b>(6,153)</b>	<b>1,217,738</b>
Selling expenses	(587,387)	(86,292)	(673,679)	(74,566)	(748,245)
Administrative expenses	(106,543)	(33,897)	(140,440)	1,242	(139,198)
Other operating income, net	1,130	1,562	2,692	(3,959)	(1,267)
<b>Operating profit</b>	<b>363,426</b>	<b>49,038</b>	<b>412,464</b>	<b>(83,436)</b>	<b>329,028</b>
Exchange difference, net	(26,270)	4,048	(22,222)	-	(22,222)
Financial income	119,369	115,318	234,687	(231,721)	2,966
Financial expenses	(216,157)	(3,304)	(219,461)	160	(219,301)
<b>Profit before income tax</b>	<b>240,368</b>	<b>165,100</b>	<b>405,468</b>	<b>(314,997)</b>	<b>90,471</b>
Income tax expense	(41,574)	(14,884)	(56,458)	24,970	(31,488)
<b>Profit for the year</b>	<b>198,794</b>	<b>150,216</b>	<b>349,010</b>	<b>(290,027)</b>	<b>58,983</b>



Notes to the interim consolidated financial statements (continued)

	Pharmacies	Manufacturing, Distribution and Marketing S/(000)	Total segments S/(000)	Holding accounts, consolidation adjustments and intercompany eliminations S/(000)	Consolidated S/(000)
<b>For the six-month period ended June 30, 2020</b>					
<b>Revenue</b>					
External income	2,503,473	878,853	3,382,326	-	3,382,326
Inter-segment	8,398	317,444	325,842	(325,842)	-
<b>Total revenue</b>	<b>2,511,871</b>	<b>1,196,297</b>	<b>3,708,168</b>	<b>(325,842)</b>	<b>3,382,326</b>
Cost of sales	(1,617,952)	(734,332)	(2,352,284)	-	(2,352,284)
Inter-segment	(7,871)	(310,335)	(318,206)	318,206	-
<b>Gross profit</b>	<b>886,048</b>	<b>151,630</b>	<b>1,037,678</b>	<b>(7,636)</b>	<b>1,030,042</b>
Selling expenses	(523,147)	(87,604)	(610,751)	(22,065)	(632,816)
Administrative expenses	(83,838)	(36,592)	(120,430)	555	(119,875)
Other operating income (expenses), net	2,655	624	3,279	-	3,279
<b>Operating profit</b>	<b>281,718</b>	<b>28,058</b>	<b>309,776</b>	<b>(29,146)</b>	<b>280,630</b>
Exchange difference, net	(26,091)	856	(25,235)	-	(25,235)
Financial income	9,404	3,666	13,070	(6,522)	6,548
Finance expenses	(92,486)	(9,860)	(102,346)	6,694	(95,652)
<b>Profit before income tax</b>	<b>172,545</b>	<b>22,720</b>	<b>195,265</b>	<b>(28,974)</b>	<b>166,291</b>
Income tax expense	(52,084)	(11,687)	(63,771)	8,283	(55,488)
<b>Profit for the year</b>	<b>120,461</b>	<b>11,033</b>	<b>131,494</b>	<b>(20,691)</b>	<b>110,803</b>

Inter-segment revenues are eliminated upon consolidation and reflected also in the “Adjustments and eliminations” column.

**Geographic information-**

As of June 30, 2021 and December 31, 2020, the operations of all the Company's subsidiaries are mainly carried out in Peru; with income and assets from abroad not being significant at those dates.

**23. Fair value**

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

When a financial instrument is traded in an active and liquid market, its quoted market price in an actual transaction provides the best evidence of its fair value. When a quoted market price is not available, or may not be indicative of the fair value of the financial instrument, other estimation techniques may be used to determine such fair value, including the current market value of another financial instrument that is substantially similar, discounted cash flow analysis or other techniques applicable, all of which are significantly affected by the assumptions used. Although Management uses its best judgment in estimating the fair value of these financial instruments, there isn't an exact estimation technique. As a result, the fair value may not be indicative of the net realizable of settlement value.

The following methods and assumptions were used to estimate the fair values:

(a) Financial instruments whose fair value is similar to book value

Assets and liabilities that are liquid or have short maturities (less than three months), such as cash and short-term deposits, trade and other receivables, trade and other payables and other current liabilities, approximate to their carrying amounts largely due to the short-term maturities of these instruments. Also, the derivative instrument by the InRetail Pharma Group is recorded at fair value.

(b) Fixed-rate financial instruments

The fair value of financial assets and liabilities at fixed interest rates and amortized cost is determined by comparing market interest rates at their initial recognition to current market rates related to similar financial instrument. The estimated fair value of interest-bearing deposits is determined through discounted cash flows by using market interest rates in the prevailing currency with similar maturities and credit risks.

(c) Investment at fair value through equity

Fair value of investment at fair value through equity is derived from quoted market prices in active markets, if available. Fair value of unquoted investment at fair value through equity is estimated using a discounted cash flow technique.

## Notes to the interim consolidated financial statements (continued)

### Fair value hierarchy

The InRetail Pharma Group uses the following hierarchy for determining and disclosing the fair value of its financial instrument recorded in the statement of financial position:

Level 1: quoted (unadjusted) prices in active markets for identical assets or liabilities.

Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly.

Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data.

The InRetail Pharma Group does not maintain any financial instrument with fair value determination under level 3 and there were no transfers between levels during the six-month period ended June 30, 2021 and 2020. The InRetail Pharma Group maintains the following financial instruments at fair value:

- Investment at fair value through equity which fair value was determined under level 1 hierarchy.
- Derivative instrument which fair value was determined under level 2 hierarchy.

### 24. Transactions in foreign currency

The financial statements have been stated in Soles using exchange rates prevailing in the market as published by the Superintendence of Banks, Insurance and Pension Funds Administration. As of June 30, 2021 the end of period exchange rates in the market for transactions in US Dollars were S/3.849 per US\$1.00 bid and S/3.866 per US\$ 1.00 ask (S/3.618 and S/3.624 per US\$1.00 for bid and ask as of December 31, 2020).

Transactions in foreign currency are carried out using exchange rates prevailing in the market as published by authorized entities of the country in which the Company and its Subsidiaries operate. As of June 30, 2021 and December 31, 2020, the end of period exchange rate at the market for transactions of the different currency in relation to the Sol are as following:

<b>Exchange rate per Soles</b>	<b>2021</b>	<b>2020</b>
U. S. Dollars (US\$)	0.259	0.276
Bolivian Peso (B\$)	1.800	1.921
Colombian Peso (\$)	-	947.158

## Notes to the interim consolidated financial statements (continued)

As of June 30, 2021 and December 31, 2020, the InRetail Pharma Group held the following foreign currency assets and liabilities:

	As of June 30, 2021		As of December 31, 2020		
	US\$(000)	b\$(000)	US\$(000)	b\$(000)	\$(000)
<b>Assets</b>					
Cash and short-term deposits	82,521	24,531	17,158	18,278	621,811
Investments at fair value through equity	13,341	-	14,942	-	-
Trade receivables, net	52,377	49,105	57,308	47,684	9,054,828
Other accounts receivables, net	9,570	4,218	4,086	4,732	-
Accounts receivable from related parties	-	-	-	-	-
<b>Total assets</b>	<b>157,809</b>	<b>77,854</b>	<b>93,494</b>	<b>70,694</b>	<b>9,676,639</b>
<b>Liabilities</b>					
Trade payables	(73,731)	(14,916)	(81,676)	(16,909)	(4,310,221)
Other payables	(6,564)	(7,255)	(8,671)	(8,111)	-
Accounts payable to related parties	(287,195)	-	(13)	-	-
Lease liability	(97,807)	(1,865)	(93,939)	(1,983)	-
Interest - bearing loans and borrowings	(13,816)	-	(417,379)	-	(2,989,968)
<b>Total Liabilities</b>	<b>(479,113)</b>	<b>(24,036)</b>	<b>(601,678)</b>	<b>(27,003)</b>	<b>(7,300,189)</b>
Call Spread	288,000	-	400,000	-	-
<b>Net (liability) assets position</b>	<b>(33,304)</b>	<b>53,818</b>	<b>(108,184)</b>	<b>43,691</b>	<b>2,376,450</b>

As of June 30, 2021 and December 31, 2020, InRetail Pharma and its Subsidiaries have decided to reduce its exchange rate risk by entering into a hedging operation through a Call Spread written over its intercompany loan with InRetail Consumer and over its "Senior Notes Unsecured", respectively, which is considered an effective hedging instrument.

The Call Spread is written over a nominal amount of US\$288,000,000 as of June 30, 2021, which protects it from exchange rate fluctuations between S/3.70 and S/4.20 and will be effective until the maturity of the intercompany loan (US\$400,000,000 as of December 31, 2020, which protects it from exchange rate fluctuations between S/3.26 and S/3.75 and was effective until the maturity of the related parties and "Senior Notes Unsecured"). See further detail in Note 8 and 13.

### 25. Subsequent event

The Company's Management and its Subsidiaries continue monitoring the evolution of the situation and the guidance of national and international authorities, since events beyond Management's control may arise that require modifying the established business plan. Further spread of COVID-19 and subsequent measures taken to limit the spread of the disease could affect the ability to conduct business in the normal way and therefore affect financial condition and results of operations.

### 26. Additional explanation for English translation

The accompanying consolidated financial statements are presented on the basis of the IFRS. Certain accounting practices applied by the InRetail Pharma Group may differ in certain respects from accounting principles generally accepted in other countries. In the event of any discrepancy, the Spanish-language version prevails.